{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_codes_comments in Code Comments (approximate match)
Status:
US Approved OTC
Source:
21 CFR 349.14(b)(3) ophthalmic:emollient paraffin
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
US Approved OTC
Source:
21 CFR 349.14(a)(2) ophthalmic:emollient lanolin (in combination)
Source URL:
First marketed in 1921
Source:
Hydrous Wool Fat U.S.P.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved OTC
Source:
21 CFR 349.14(b)(5) ophthalmic:emollient white ointment
Source URL:
First marketed in 1921
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01483287: Early Phase 1 Interventional Completed Irritable Bowel Syndrome
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE